(Hong Kong, 14 October 2025) — The Hong Kong Science and Technology Parks Corporation (HKSTP) and Advanced Isotopes Technology Asia Ltd. (AITA) today held the launch ceremony for the "Driving Forward Hong Kong's New Industrialisation - New Industrialisation Acceleration Scheme (NIAS)" project at Tai Po InnoPark. This marks AITA’s plan to land in Tai Po InnoPark, where the company will set up a compact medical superconducting cyclotron and isotope drugs production line, introducing cutting-edge medical technology to Hong Kong and reinforcing the city’s leadership in innovation and technology (I&T).
The ceremony was officiated by Professor Sun Dong, Secretary for Innovation, Technology and Industry; Mr Ivan Lee, Commissioner for Innovation and Technology; Dr Ge Ming, Commissioner for Industry (Innovation and Technology); Dr Sunny Chai, Chairman of HKSTP; Mr Terry Wong, Chief Executive Officer of HKSTP; Mr Zhu Chunxiao, Co-founder and CEO of AITA; and Dr Li Ying, Co-founder of AITA, marking another significant milestone in Hong Kong's new industrialisation journey.
Professor Sun Dong, Secretary for Innovation, Technology and Industry, said: "The Government has remained committed to leveraging technological innovation to drive industrial innovation, actively advancing Hong Kong’s transition towards new industrialisation. We place particular emphasis on introducing frontier technologies from both domestic and international sources, using them as a foundation for the development of local industries. This approach supports the construction and upgrading of the industry value chain and promotes high-quality economic growth. The project launched today is a concrete example of this strategic direction. We are pleased to see a growing number of outstanding innovation and technology enterprises, such as AITA, bringing frontier technologies from overseas to Hong Kong. These companies are establishing research and development, pilot testing, and production facilities locally, and are leveraging Hong Kong’s international platform to propel their products and services into the global market."
Accelerating Hong Kong's New Industrialisation Together
The HKSAR Government clearly set forth the drive for "new industrialisation" in the “Hong Kong Innovation and Technology Development Blueprint” and launched the HK$10 billion NIAS, focusing on strategic I&T industries including life and health technology, advanced manufacturing, and new energy technology industries. AITA's project received support from the New Industrialisation Vetting Committee, with approximately HK$140 million expected to be funded under the NIAS; and AITA’s total investment for the project is about HK$600 million, including production facilities and factory renovation. Following the first approved project earlier, this newly supported project further demonstrates the Government's sustained and strong support for establishing the life and health technology industry in Hong Kong, as we strive to steer the city towards a higher value-added new industrialisation path in alignment with the national direction of developing new quality productive forces.
First Commercial Production of Ac-225 Isotope Strengthening Hong Kong's Life and Health Technology Industry
Established in 2024 and headquartered in Hong Kong, AITA specialises in the research, development and production of medical superconducting cyclotrons, establishing nuclear pharmacies and producing isotope drugs. The company plans to establish two alpha isotope drugs production lines and one compact superconducting cyclotron production line at Tai Po InnoPark. AITA will produce and sell 12.5MeV compact medical superconducting cyclotrons whilst independently developing 16.5MeV superconducting cyclotrons. The company will also establish multiple nuclear pharmacies producing isotope drugs including F-18, N-13 and Ga-68 PSMA. By 2027, AITA expects to commence production of Ac-225 isotope drugs in Hong Kong, which is currently in critically short supply globally. This will mark the first production in Asia of this essential raw material for targeted isotope drugs currently undergoing Phase III clinical trials, benefiting patients across the region.
Leveraging Hong Kong as an Asian hub, AITA brings overseas cutting-edge technology with target markets spanning mainland China, Japan, South Korea, Singapore and Southeast Asia. The company plans to collaborate with local tertiary institutions to develop next-generation superconducting cyclotrons, building independent intellectual property, strengthening local research capabilities and nurturing talent, whilst attracting overseas scientists and engineers to enhance local and international knowledge exchange.
HKSTP's Comprehensive Support Drives Industry Synergy
Dr Sunny Chai, Chairman of HKSTP, remarked: "HKSTP actively supports the HKSAR Government's push for new industrialisation and the national development of new quality productive forces, fully backing the growth of the life and health technology industry. AITA's establishment enriches our biotechnology industry landscape and drives diversified development across the medical technology and advanced manufacturing value chains. We will continue to promote industry-academia-research collaboration and facilitate technology transfer and commercialisation, working to establish Hong Kong as Asia's leading life and health technology hub, injecting new momentum into the city's economic development and consolidating our position as an international I&T centre."
Dr Kevin Cameron, Co-Founder of AITA, stated: "We are proud to introduce this unique and globally rare superconducting cyclotron technology to Hong Kong for the first time, marking the first of its kind in Asia. This innovative technology will support the production of radioisotopes for both diagnosis and treatment, aiding the early detection and treatment of cancer. The project will bring not only unique technology and specialised jobs, but also significant medical breakthroughs for local and regional patients. We look forward to working hand in hand with partners from all sectors to advance the field of radiopharmaceuticals and establish Hong Kong as a hub of radiopharmaceutical innovation in Asia."
HKSTP supports the Government's new industrialisation and new quality productivity policies through world-class infrastructure including the Tai Po Medical Technology Manufacturing Centre (MARS), GMP Centre, Tseung Kwan O Advanced Manufacturing Centre (AMC) and Yuen Long Microelectronics Centre (MEC), providing comprehensive support to enterprises. Following AITA's establishment at Tai Po InnoPark, the company will create valuable synergies with other enterprises within HKSTP's innovation ecosystem, accelerating the diversified development of life and health technology and advanced manufacturing industries whilst strengthening Hong Kong's position as a global innovation and technology hub.
